FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

8 letters match. Newest first.

  1. ABBE Laboratories, Inc.

    FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.

    High risk
  2. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk
  3. Laboratoire Druide Inc.

    FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

    High risk
  4. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  5. Sol-ti Inc.

    FDA found Sol-ti's ready-to-drink juices lacked validated pathogen controls and required safety monitoring.

    High risk
  6. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  7. Zhejiang Tianyu Pharmaceutical Co., Ltd.

    Zhejiang Tianyu Pharmaceutical made active pharmaceutical ingredients (API) with current good manufacturing practice (CGMP) deviations in impurity investigations and equipment cleaning.

    High risk
  8. Proquimes S A Productos Quimicos Especializados S.A.

    FDA warned Proquimes S.A. that its active pharmaceutical ingredient manufacturing violated current good manufacturing practice (CGMP) because process, equipment, and cleaning validation were missing.

    High risk